Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN Z versus TRYVIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN Z versus TRYVIO.
TRAVATAN Z vs TRYVIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
Tryvio (vobadimustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes HIF-α, leading to increased erythropoietin production and stimulation of erythropoiesis.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
Adults: 0.25 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Terminal elimination half-life 44-60 hours in healthy adults; prolonged in hepatic impairment (up to 120 hours).
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Primarily hepatic metabolism; 90% as inactive metabolites in feces, <5% unchanged in urine; <5% in bile.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog